Browsing by Author "Gatalica, Zoran"
Now showing items 21-34 of 34
-
Nutm1-rearranged neoplasms: A heterogeneous group of primitive tumors with expanding spectrum of histology and molecular alterations: An updated review
Luo, Wenyi; Stevens, Todd M.; Stafford, Phillip; Miettinen, Markku; Gatalica, Zoran; Vranic, Semir... more authors ... less authors ( MDPI , 2021 , Article)Nuclear protein of testis (NUT), a protein product of the NUTM1 gene (located on the long arm of chromosome 15) with highly restricted physiologic expression in post-meiotic spermatids, is the oncogenic driver of a group ... -
PD-L1 status in breast cancer: Current view and perspectives.
Vranic, Semir; Cyprian, Farhan S; Gatalica, Zoran; Palazzo, Juan ( Elsevier , 2019 , Article)Breast cancer was traditionally not considered a particularly immunogenic tumor. However, recent developments have shown that some aggressive triple-negative breast cancers are immunogenic, exhibit a resistance to chemotherapy ... -
PD-L1 testing by immunohistochemistry in Immuno-Oncology.
Vranic, Semir; Gatalica, Zoran ( Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina , 2022 , Article Review)Immunotherapy, based on immune checkpoint inhibitors targeting the Programmed cell death ligand 1 (PD-L1) and/or Programmed Death Receptor 1 (PD-1), has substantially improved the outcomes of patients with various cancers. ... -
Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast.
Vranic, Semir; Palazzo, Juan; Sanati, Souzan; Florento, Elena; Contreras, Elma; Xiu, Joanne; Swensen, Jeffrey; Gatalica, Zoran... more authors ... less authors ( Elsevier , 2018 , Article)Neuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does not have a specific targeted therapy, several new ... -
The Role of Pathology in the Era of Personalized (Precision) Medicine: A Brief Review.
Vranic, Semir; Gatalica, Zoran ( NLM (Medline) , 2021 , Article)This review provides a brief overview of the state-of-the-art molecular pathology approaches emphasizing the increasingly important pathology role in clinical precision cancer medicine. Recent advances in molecular biology ... -
Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer.
Cyprian, Farhan S; Akhtar, Saghir; Gatalica, Zoran; Vranic, Semir ( Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina , 2019 , Article Review)The treatment of several solid and hematologic malignancies with immune checkpoint inhibitors (against PD-1/PD-L1) has dramatically changed the cancer treatment paradigm. However, no checkpoint inhibitors were previously ... -
Targeting HER2 expression in cancer: New drugs and new indications.
Vranic, Semir; Gatalica, Zoran ( Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina , 2020 , Article)Functional activation of human epidermal growth factor receptor 2 (HER2) has been shown to strongly promote carcinogenesis, leading to the investigation of HER2-directed agents in cancers with HER2 genomic alterations. ... -
TERT gene fusions characterize a subset of metastatic Leydig cell tumors
Bozo, Kruslin; Gatalica, Zoran; Hes, Ondrej; Skenderi, Faruk; Miettinen, Markku; Contreras, Elma; Xiu, Joanne; Elis, Michelle; Florento, Elena; Vranic, Semir; Swensen, Jeffrey... more authors ... less authors ( Elsevier , 2021 , Article)Objective: Metastatic Leydig cell tumors (LCT) are rare, difficult to treat malignancies without known underlying molecular-genetic events. An index case of metastatic LCT showed an LDLR-TERT gene fusion upon routine genetic ... -
Theranostic molecular profiling of pleomorphic ductal carcinoma of the breast.
Vranic, Semir; Palazzo, Juan; Swensen, Jeffrey; Xiu, Joanne; Florento, Elena; Gatalica, Zoran... more authors ... less authors ( Wiley , 2019 , Other)Pleomorphic ductal carcinoma (PDC) is a very rare subtype of invasive ductal carcinoma of no‐special type (NST), characterized by the presence of highly atypical/bizarre (>6‐fold variation in nuclear size) and multinucleated ... -
Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies.
Willenbacher, Wolfgang; Seeber, Andreas; Steiner, Normann; Willenbacher, Ella; Gatalica, Zoran; Swensen, Jeff; Kimbrough, Jeffery; Vranic, Semir... more authors ... less authors ( MDPI , 2018 , Article)Multiple myeloma (MM), the second most common hematologic malignancy, is characterized by the clonal expansion of plasma cells. Despite dramatic improvements in patients' survival over the past decade due to advances in ... -
Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers
Vranic, Semir; Gatalica, Zoran ( Association of Basic Medical Sciences of FBIH , 2022 , Article)Antibody-drug conjugates represent a new class of highly potent antineoplastic drugs built by attaching a small molecule of an anticancer drug (payload) or another therapeutic agent to an antibody recognizing an epitope ... -
Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group
Vranic, Semir; Basu, Gargi D.; Hall, David W.; Gatalica, Zoran ( Academy of Sciences and Arts of Bosnia and Herzegovina , 2022 , Article)In the present review, we briefly discuss the breakthrough advances in precision medicine using a tumor-agnostic approach and focus on BRAF treatment modalities, the mechanisms of resistance and the diagnostic approach in ... -
An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the Breast
Semir, Vranic; Gatalica, Zoran ( Elsevier , 2021 , Article)Apocrine carcinoma of the breast is a rare malignancy. According to 2019 WHO classification, apocrine cellular features and a characteristic steroid receptor profile (Estrogen receptor (ER)-negative and androgen receptor ... -
An Updated Review of the Biomarkers of Response to Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: Merkel Cell Carcinoma and Immunotherapy
Fojnica, Adnan; Ljuca, Kenana; Akhtar, Saghir; Gatalica, Zoran; Vranic, Semir ( Multidisciplinary Digital Publishing Institute (MDPI) , 2023 , Article)Merkel cell carcinoma (MCC) is primarily a disease of the elderly Caucasian, with most cases occurring in individuals over 50. Immune checkpoint inhibitors (ICI) treatment has shown promising results in MCC patients. ...